enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Sotatercept - Wikipedia

   en.wikipedia.org/wiki/Sotatercept

   In the United States, sotatercept is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1). [6] [10]In the European Union, sotatercept, in combination with other pulmonary arterial hypertension therapies, is indicated for the treatment of pulmonary arterial hypertension in adults with WHO Functional Class (FC) II to III, to improve exercise capacity.

3. Selexipag - Wikipedia

   en.wikipedia.org/wiki/Selexipag

   Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]

4. Brilaroxazine - Wikipedia

   en.wikipedia.org/wiki/Brilaroxazine

   RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...

5. 19 drug approvals in 2024 that had 'big clinical impact ... - AOL

   www.aol.com/news/19-drug-approvals-2024-had...

   GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact."

6. Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%

   www.aol.com/news/arena-arna-licenses-rights-pah...

   Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.

7. What You Need to Know About PAH Drugs in 2014 - AOL

   www.aol.com/2013/12/31/what-you-need-to-know...

   A host of newly approved drugs for pulmonary arterial hypertension, or PAH, means 2014 will be a battleground for market share in the multibillion-dollar indication. Among those competing will be ...